Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EASTMAN KODAK COKODK · Entity 5053 | General Counsel, Sec., SVP | December 15, 2018 | January 11, 2019 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | EVP, GC & Corporate Secretary | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EASTMAN KODAK CO
Report date December 15, 2018 · Filed January 11, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2025-12-14 | Direct | 139,665 |
Reported balance
After 2018-12-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-12-15 · Grant · Acquired 139,665 · Balance 139,665 F1: Ms. Underberg previously reported this option on her 12/15/2018 Form 4; however, at that time, the number of shares underlying the option could not be determined. Ms. Underberg is filing this amendment to report the number of shares underlying the option. This option vests one-third on each of the first three anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Underberg previously reported this option on her 12/15/2018 Form 4; however, at that time, the number of shares underlying the option could not be determined. Ms. Underberg is filing this amendment to report the number of shares underlying the option. This option vests one-third on each of the first three anniversaries of the grant date.
IDEXX LABORATORIES INC /DE
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,137.654 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Exercise / conversion · Acquired 197 · Balance 7,137.654 |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-03 · Exercise / conversion · Disposed 197 · Balance 0 F2: Not applicable. F1: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0000874716-26-000050 · wk-form4_1772748092.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 197 | $505.53 | $99,589.41 |
DisclosureSEC source: 0000874716-26-000050 · wk-form4_1772748092.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,137.654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 12 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 795 Underlying: Common Stock · 265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 11 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434 Underlying: Common Stock · 218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 10 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 9 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 251 | $629.35 | $157,966.85 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · nonDerivative · entry 5 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,940.654 F2 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · nonDerivative · entry 4 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,191.654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · nonDerivative · entry 3 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,926.654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · nonDerivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,708.654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,532.654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 333.654 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 891 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 8 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 891 Underlying: Common Stock · 891 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 7 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,738 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000027 · wk-form4_1771374673.xml · derivative · entry 6 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,738 Underlying: Common Stock · 3,738 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 183 | $0.00 Strike: $544.08 | $0.00 |
DisclosureSEC source: 0000874716-25-000135 · wk-form4_1755032434.xml · derivative · entry 5 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183 shares Expires 2031-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 183 | $544.08 | $99,566.64 |
DisclosureSEC source: 0000874716-25-000135 · wk-form4_1755032434.xml · nonDerivative · entry 3 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,338.6539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,450 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-25-000135 · wk-form4_1755032434.xml · derivative · entry 4 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,450 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in four annual installments beginning on February 14, 2020. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,450 | $651.60 | $3,551,220.00 |
DisclosureSEC source: 0000874716-25-000135 · wk-form4_1755032434.xml · nonDerivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,155.6539 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,450 | $206.94 | $1,127,823.00 |
DisclosureSEC source: 0000874716-25-000135 · wk-form4_1755032434.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,605.6539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 12 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652 Underlying: Common Stock · 218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 11 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 10 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 137 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 9 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 219 | $444.53 | $97,352.07 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · nonDerivative · entry 5 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,126.9449 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · nonDerivative · entry 4 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,345.9449 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · nonDerivative · entry 3 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,127.9449 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · nonDerivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,951.9449 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 137 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,778.9449 F1 · balance_after: Includes a total of 47 shares purchased under the Issuer Employee Stock Purchase Plan on March 29, 2024, June 28, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 8 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060 Underlying: Common Stock · 1,060 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 7 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,504 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000030 · wk-form4_1739933040.xml · derivative · entry 6 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,504 Underlying: Common Stock · 4,504 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0000874716-24-000048 · wk-form4_1708466445.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-24-000048 · wk-form4_1708466445.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,594.9449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 14 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 13 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 138 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 12 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137 Underlying: Common Stock · 138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 11 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 483 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 10 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 9 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 870 Underlying: Common Stock · 870 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 8 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,856 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 7 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,856 Underlying: Common Stock · 3,856 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 356 | $560.56 | $199,559.36 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 6 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,111.9449 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 5 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,467.9449 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 4 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,291.9449 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 138 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 3 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,118.9449 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,980.9449 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 483 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,764.9449 F1 · balance_after: Includes a total of 37.247 shares purchased under the Issuer Employee Stock Purchase Plan on June 30, 2023, September 29, 2023 and December 29, 2023. Read SEC document |
| May 05, 2023 Filed May 8, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock · Derivative | 483 | Not disclosed Strike: $206.92 | Not disclosed |
DisclosureSEC source: 0000874716-23-000044 · wf-form4_168357986086502.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. Read SEC document |
| May 05, 2023 Filed May 8, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-23-000044 · wf-form4_168357986086502.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,244.6979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003224 · doc1.xml · derivative · entry 9 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,197 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.